Graypoint LLC Acquires 146 Shares of SPDR S&P Biotech ETF (NYSEARCA:XBI)

Graypoint LLC grew its holdings in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 5.6% during the third quarter, Holdings Channel reports. The firm owned 2,738 shares of the exchange traded fund’s stock after purchasing an additional 146 shares during the period. Graypoint LLC’s holdings in SPDR S&P Biotech ETF were worth $271,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of XBI. Mirae Asset Global Investments Co. Ltd. grew its stake in SPDR S&P Biotech ETF by 15.2% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 29,320 shares of the exchange traded fund’s stock valued at $2,782,000 after buying an additional 3,860 shares during the last quarter. Csenge Advisory Group acquired a new position in SPDR S&P Biotech ETF in the 1st quarter valued at $207,000. Geneos Wealth Management Inc. grew its stake in SPDR S&P Biotech ETF by 10.4% in the 1st quarter. Geneos Wealth Management Inc. now owns 1,541 shares of the exchange traded fund’s stock valued at $146,000 after buying an additional 145 shares during the last quarter. Concurrent Investment Advisors LLC grew its stake in SPDR S&P Biotech ETF by 13.2% in the 1st quarter. Concurrent Investment Advisors LLC now owns 2,564 shares of the exchange traded fund’s stock valued at $243,000 after buying an additional 299 shares during the last quarter. Finally, Choate Investment Advisors grew its stake in SPDR S&P Biotech ETF by 144.8% in the 1st quarter. Choate Investment Advisors now owns 24,186 shares of the exchange traded fund’s stock valued at $2,295,000 after buying an additional 14,307 shares during the last quarter.

SPDR S&P Biotech ETF Trading Up 1.1 %

NYSEARCA:XBI opened at $104.18 on Friday. The firm has a market capitalization of $7.94 billion, a PE ratio of 11.47 and a beta of 1.11. The firm’s fifty day simple moving average is $98.96 and its 200 day simple moving average is $95.60. SPDR S&P Biotech ETF has a 1 year low of $64.99 and a 1 year high of $104.22.

SPDR S&P Biotech ETF Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.